Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak


Photo caption: Rwanda Minister of State for Health, Yvan Butera, was among those who received Sabin’s investigational vaccine in the open-label clinical trial.

WASHINGTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- In continued collaboration with Rwanda to address the Marburg virus outbreak, the Sabin Vaccine Institute has dispatched approximately 1,000 additional investigational vaccine doses for a randomized clinical trial arm within the ongoing open-label study. More than 1,500 frontline workers have already been vaccinated in Rwanda with the Sabin vaccine.

Under the updated protocol, sponsored by the Rwanda Biomedical Center, approximately 1,000 at-risk individuals, including mine workers, will receive Sabin’s single-dose investigational vaccine in a 1-to-1 randomization. Half will receive the vaccine immediately, and the other half 21 days later to align with the end of the disease incubation period.

Genomic sequencing of the index case (first identified case in an infectious disease outbreak) in Rwanda suggests a zoonotic origin, with strains similar to those found in fruit bats in a mine.

The new trial arm will assess safety, immunogenicity, and efficacy. Pending a request from Rwandan officials and authorization from the U.S. Administration for Strategic Response and Preparedness, Sabin plans to supply additional vaccines for this portion of the trial.

“As Rwandan health officials determined, the most expeditious and effective way to reach this new group of people impacted by the outbreak is to adapt the current protocol,” says Sabin CEO Amy Finan. “While this vaccine is still investigational, our mission is to ensure that knowledge can move swiftly from research to real-world solutions, with scientific rigor and safety as our highest priorities.”

At a news conference today about the Marburg outbreak, Rwanda minister of state for health Yvan Butera also addressed the need for more vaccine doses. Since the outbreak began, Sabin has been working directly with Rwandan officials and partners to mount a coordinated response.

As in previous outbreaks, Sabin continues to collaborate closely with its contract manufacturer, ReiThera, to prepare and ship the vialed doses to Rwanda.

Over 1,700 vaccines have already been delivered to Rwanda, with the first shipment of doses arriving just nine days after the outbreak was declared on September 27. The initial part of the trial focused largely on health workers, a group that suffered the most casualties in this outbreak.

Rwanda has confirmed 66 Marburg cases in what is one of the largest recorded outbreaks of the disease. Case numbers declined sharply within two weeks, with 15 deaths reported so far. The case-fatality rate, approximately 23%, remains significantly lower than previous outbreaks, which have seen mortality rates as high as 88%.

Designed to prevent illness before exposure to the virus, Sabin’s Marburg vaccine has not yet been proven to have clinical benefit for recipients of the vaccine. The candidate is currently in Phase 2 trials in Uganda and Kenya with no safety concerns reported to date. In non-human primates, it has demonstrated rapid immunity within one week, and in Phase 1 trials, it has shown safety and immunogenicity in humans.

Marburg virus disease remains a serious threat, with a high case fatality rate, and no approved vaccines currently available. Symptoms typically emerge between two and 21 days after infection.

Since 2019, Sabin has been at the forefront of advancing vaccines for filoviruses based on the cAd3 platform. Interim results from the Marburg trial are expected next year, with a U.S.-based trial planned for 2025. Sabin is also a key partner in MARVAC, a WHO-coordinated effort promoting global collaboration in Marburg vaccine development.

Sabin’s development program, which includes clinical trials and manufacturing of clinical trial material that have been leveraged for this current outbreak, is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under multi-year contracts. To date, BARDA has obligated $235 million to Sabin for advancing vaccine research and development against Sudan ebolavirus and Marburg virus diseases.

In addition to BARDA and Rwanda’s government, Sabin is grateful for all the organizations including CEPI, GSK, IQVIA, kENUP Africa, National Institutes of Health’s Vaccine Research Center, PPD, WHO, and World Courier who have contributed to our past and current efforts.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f38d0939-533d-4fea-8d71-882be4461b28


Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak

THỦ THUẬT HAY

Cài đặt tinh chỉnh FullScreenX cho các game và ứng dụng chưa hỗ trợ trên iPhone X

Về cơ bản, tweak này sẽ nhân đôi những khoảng trống trong thiết kế của ứng dụng, nhằm kéo dài giao diện cho phù hợp với tỉ lệ khung hình và nâng cao khả năng hiển thị trên iPhone X. Để tải về FullScreenX, bạn cần thực

Cách tra cứu kết quả đóng BHXH, BHYT, BHTN

Giờ đây, chỉ cần có kết nối mạng Internet bạn có thể tra cứu mã số bảo hiểm xã hội (BHXH), quá trình tham gia BHXH trực tuyến vô cùng nhanh chóng, mà không phải tốn công lên cơ quan BHXH như trước đây nữa.

Cách bỏ thích Fanpage Facebook hàng loạt đơn giản, ai cũng làm được

Hướng dẫn bạn cách bỏ thích hàng loạt Fanpage Facebook trên điện thoại, máy tính để tránh phải đọc những bài viết từ các trang mà bạn chưa bao giờ theo dõi đến. Click xem ngay nhé!

Hướng dẫn trải nghiệm âm thanh 3D với tai nghe trên Windows 10

Âm thanh vòm (surround) là hệ thống âm thanh phát ra từ nhiều hướng bao quanh người nghe, tạo thành một vòm âm thanh và làm cho người nghe có cảm giác âm thanh khá chân thực. Các âm thanh này cho người nghe trải nghiệm

Cách thay đổi trình duyệt mặc định trên Windows 10

Microsoft Edge là trình duyệt mặc định trên Windows 10, tuy nhiên bạn hoàn toàn có thể đổi sang Google Chrome hay Mozilla Firefox nếu muốn.

ĐÁNH GIÁ NHANH

Cùng xem cuộc so găng giữa Canon 77D và Nikon D7500

77D – sản phẩm có số serie rất đặc biệt của Canon đang được đưa lên bàn cân để so sánh với chiếc máy mới ra mắt của Nikon là D7500. Xét về phân khúc thì cả hai đều thuộc dòng semi-pro trong khi thời gian ra mắt cũng

Đánh giá GoldTV SE1 - Bluetooth: dàn loa cho TV, smartphone

Đây là mẫu sản phẩm mới nhất của công ty loa GoldSound. Có thể thấy GoldSound tích cực ra mắt nhiều mẫu mã và chủng loại. Trong vòng vài tháng trở lại đây, công ty này đã ra mắt...

Đánh giá nhanh tai nghe không dây Samsung Gear IconX

Ra mắt trước Apple Airpod đến tận 2 tháng, Gear IconX thuộc dòng phụ kiện Gear của Samsung và là đối thủ ngang sức với thế hệ tai nghe không dây...